Grants / Department of Defense / Defense Health Agency Contracting Activity - DHACA

W81XWH-21-PRARP-ADRA: DOD Peer Reviewed Alzheimer’s, Accelerating Diagnostics Research Award

Closed Closed July 21, 2021 Opportunity W81XWH-21-PRARP-ADRA ☆ Save

This grant is closed. A newer notice from the same program is open now: DoW Breast Cancer, Clinical Research Extension Award (HT942526BCRPCREA2). Status: Closes November 18, 2026 (11 days left). It is in our archive of Defense Health Agency Contracting Activity - DHACA notices from 2021.

• Total funding$15.0 million
• Expected awards1
• Cost sharingNot required
• Funding typeCooperative Agreement, Grant

Key dates

Who can apply

This opportunity was open to any type of organization.

• Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility"

More grants for nonprofits, colleges and universities, state and local governments, tribes, small businesses, businesses, individuals.

Is this a realistic fit?

• Most of the program's money (59% over five years) went to colleges and universities.
• No cost sharing or match is required.

What the grant funds

The intent of the FY21 PRARP ADRA is to support high-impact, human-based development of robust diagnostic and/or prognostic biomarkers for military risk factors that pertain to AD/ADRD. It is anticipated that the proposed work will qualify clinically useful biomarkers for rapid transfer to clinical practice. The FY21 PRARP ADRA mechanism defines biomarker qualification as the evidentiary process of linking a biomarker with biological processes and clinical endpoints. Applications may consider elements of biomarker validation as part of the application. Biomarker validation is defined as assessing the biomarker’s measurement performance characteristics in terms of reproducibility, accuracy, precision, and limits of sensitivity. Applications that detail biomarker validation work should demonstrate how this research is relevant to overall biomarker qualification. As part of the application, the proposed biomarkers should demonstrate their potential for improved specificity and sensitivity with respect to diagnosis and/or prognosis of AD/ADRD as the study endpoint. The FY21 PRARP ADRA does not support basic discovery of biomarkers. As such, animal research is prohibited. The proposed biomarker for investigation must correlate with clinical endpoints to include cognition and/or behavior relevant to military risk factor-related research and AD/ADRD. As part of the application, the Principal Investigator (PI) should demonstrate that the study team has experience in both military risk factor-related research and AD/ADRD. The FY21 PRARP ADRA encourages applications to consider fluid-based, imaging-based, retinal, or wearable devices as potential diagnostics. Applications must provide a plan that demonstrates access to a suitable cohort and a plan for participant accrual. Suitable cohorts must be relevant to the military risk factor identified as part of the application. Due to nature of the FY21 PRARP ADRA, studies are required to prospectively recruit study participants. Applications must therefore describe how the anticipated outcome(s) can be attributable to the results of the proposed research (short-term gains), as well as consider the long-term scientific gains from the proposed research project. FY21 PRARP ADRA applications must be impact-based.

Category: Science and Technology and other Research and Development.

Applying now

This notice no longer takes applications. Apply under the newer notice, HT942526BCRPCREA2, which is open now.

The notice on Grants.gov keeps its full text and attachments, which is useful for planning a resubmission.